Coeptis Therapeutics (COEPW) Competitors $0.03 +0.00 (+10.78%) As of 03:41 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends COEPW vs. ATNFW, SXTPW, DRTSW, WENAW, APLMW, BCTXW, CDIOW, CTCXW, CELUW, and CEROWShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Anew Medical (WENAW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), Celularity (CELUW), and CERo Therapeutics (CEROW). These companies are all part of the "biotechnology" industry. Coeptis Therapeutics vs. 180 Life Sciences 60 Degrees Pharmaceuticals Alpha Tau Medical Anew Medical Apollomics BriaCell Therapeutics Cardio Diagnostics Carmell Celularity CERo Therapeutics 180 Life Sciences (NASDAQ:ATNFW) and Coeptis Therapeutics (NASDAQ:COEPW) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation. Is ATNFW or COEPW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Coeptis Therapeutics N/A N/A N/A Does the media favor ATNFW or COEPW? In the previous week, 180 Life Sciences had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 5 mentions for 180 Life Sciences and 3 mentions for Coeptis Therapeutics. 180 Life Sciences' average media sentiment score of 1.88 beat Coeptis Therapeutics' score of 1.51 indicating that 180 Life Sciences is being referred to more favorably in the media. Company Overall Sentiment 180 Life Sciences Very Positive Coeptis Therapeutics Very Positive Does the MarketBeat Community favor ATNFW or COEPW? 180 Life Sciences and Coeptis Therapeutics both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperform180 Life SciencesN/AN/ACoeptis TherapeuticsN/AN/A Which has stronger valuation & earnings, ATNFW or COEPW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/ACoeptis TherapeuticsN/AN/AN/AN/AN/A Summary180 Life Sciences beats Coeptis Therapeutics on 2 of the 2 factors compared between the two stocks. Ad StocksToTradeLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!Click here to review Tim’s special offer before it’s too late. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEPW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEPW vs. The Competition Export to ExcelMetricCoeptis TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$176.13M$5.24B$9.10BDividend YieldN/A3.64%5.31%4.19%P/E RatioN/A113.3987.4417.31Price / SalesN/A18,593.581,103.16141.28Price / CashN/A13.0143.3337.88Price / BookN/A9.505.175.13Net IncomeN/A-$20.89M$121.58M$227.11M7 Day PerformanceN/A4.36%4.89%3.71%1 Month PerformanceN/A222.57%21.07%4.67%1 Year PerformanceN/A154.21%31.88%21.06% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPWCoeptis TherapeuticsN/A$0.03+10.8%N/AN/A$0.00N/A0.004Positive NewsGap DownATNFW180 Life SciencesN/A$0.01+8.0%N/A+130.4%$0.00N/A0.007Positive NewsGap DownSXTPW60 Degrees PharmaceuticalsN/A$0.04+23.2%N/A-71.0%$0.00$502,409.000.002Positive NewsGap UpDRTSWAlpha Tau MedicalN/A$0.22flatN/A+0.8%$0.00N/A0.0080Positive NewsGap UpWENAWAnew MedicalN/A$0.04-0.3%N/AN/A$0.00N/A0.00N/AGap DownAPLMWApollomicsN/A$0.01-3.1%N/A-57.4%$0.00N/A0.0059Positive NewsGap UpBCTXWBriaCell TherapeuticsN/A$0.29+3.7%N/A-90.5%$0.00N/A0.008Positive NewsGap UpCDIOWCardio DiagnosticsN/A$0.08-14.8%N/A-48.6%$0.00$35,688.000.007Positive NewsGap DownCTCXWCarmellN/A$0.04flatN/A-76.1%$0.00$32,839.000.009Positive NewsCELUWCelularityN/A$0.02+13.2%N/A-58.0%$0.00$48.20M0.00220Positive NewsGap UpCEROWCERo TherapeuticsN/A$0.01+3.3%N/AN/A$0.00N/A0.008Positive NewsGap Up Related Companies and Tools Related Companies ATNFW Competitors SXTPW Competitors DRTSW Competitors WENAW Competitors APLMW Competitors BCTXW Competitors CDIOW Competitors CTCXW Competitors CELUW Competitors CEROW Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COEPW) was last updated on 1/7/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk says U.S. government is going bankruptIn 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $...Brownstone Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
